First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer

Published:2014-09-09 Issue:21 Volume:20 Page:5359-5364
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Amiri-Kordestani Laleh,Wedam Suparna,Zhang Lijun,Tang Shenghui,Tilley Amy,Ibrahim Amna,Justice Robert,Pazdur Richard,Cortazar Patricia

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances from targeted therapy for non‐metastatic HER2‐positive inflammatory breast cancer;Journal of Surgical Oncology;2024-08-05

2. Breast Cancer Stem Cells and Tumor Heterogeneity: Characteristics and Therapeutic Strategies;Cancers;2024-07-07

3. A clinical systematic literature review of treatments among patients with advanced and/or metastatic human epidermal growth factor receptor 2 positive breast cancer;Journal of Comparative Effectiveness Research;2024-06

4. Current Immunotherapy Treatments of Primary Breast Cancer Subtypes;Biomedicines;2024-04-18

5. Postradical prostatectomy prostate‐specific antigen outcomes after 6 versus 18 months of perioperative androgen‐deprivation therapy in men with localized, unfavorable intermediate‐risk or high‐risk prostate cancer: Results of part 2 of a randomized phase 2 trial;Cancer;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP